JOHN KALIL ERBAN, MD
Osteopathic Medicine in Boston, MA
License number
Massachusetts 57867
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
2
800 Tufts Medical Ctr, Boston, MA 02111
8 Hancock Rd, Wakefield, MA 01880
8 Hancock Rd, Wakefield, MA 01880
Phone
(617) 636-8077
(781) 246-3008
(781) 246-3008
Professional information
John Kalil Erban, Boston MA
Specialties:
Oncologist
Address:
800 Washington St, Boston, MA 02111
Education:
Tufts University, School of Medicine - Doctor of Medicine*
Harvard University - Bachelor of Arts (AB)*
Beth Israel Deaconess Medical Center - Fellowship - Oncology (Internal Medicine)*
Hospital of the University of Pennsylvania - Residency - Internal Medicine*
Harvard University - Bachelor of Arts (AB)*
Beth Israel Deaconess Medical Center - Fellowship - Oncology (Internal Medicine)*
Hospital of the University of Pennsylvania - Residency - Internal Medicine*
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine*, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine)*, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)*
Method For Predicting The Need For Dose Reductions In Chemotherapy For Patients With Breast Cancer: A Potential Decision Aid For The Use Of Myeloid Growth Factors
US Patent:
2002003, Mar 28, 2002
Filed:
Jun 25, 2001
Appl. No.:
09/891089
Inventors:
Panos Savvides - Boxford MA, US
Norma Terrin - Jamaica Plain MA, US
John Erban - Wakefield MA, US
Harry Selker - Wellesley MA, US
Norma Terrin - Jamaica Plain MA, US
John Erban - Wakefield MA, US
Harry Selker - Wellesley MA, US
International Classification:
A01N001/00
US Classification:
435/001100
Abstract:
The invention provides provided a method and instrument for predicting the probability of a patient requiring a significant dose reduction in adjuvant chemotherapy for breast cancer and/or predicting whether early treatment with a myeloid growth factor is warranted, by determining the patient's dose-adjusted nadir absolute neutrophil count (ANC) in the first cycle of the chemotherapy schedule, further determining the patient's dose-adjusted percent change in platelet count from day one to the dose-adjusted nadir platelet count in the first cycle of the chemotherapy schedule, and then calculating the probability that the patient will receive a suboptimal chemotherapy dose using the dose-adjusted nadir ANC and dose-adjusted percent change in platelet count.